Moderate to Severe Psoriasis Market Growth, Trends, Consumer Demand and Key Opportunities

Introduction
Psoriasis is a chronic, immune-mediated skin disorder marked by red, scaly plaques that can cause significant physical discomfort and psychological burden. Among the different types, moderate to severe psoriasis requires systemic therapy or biologics due to its extensive nature and comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71343

Historically, management involved topical corticosteroids, phototherapy, and systemic drugs like methotrexate or cyclosporine. The treatment paradigm, however, has shifted dramatically with the approval of biologics, targeted oral small molecules (JAK/TYK2 inhibitors), and biosimilars, reshaping disease outcomes and accessibility. With advances in precision medicine, digital dermatology, and patient advocacy, the global market is projected to expand significantly through 2034.

Market Overview
• Market Size 2024: USD 17 billion
• Forecast 2034: USD 38 billion
• CAGR (2025-2034): 8%

The market for moderate to severe psoriasis is set for robust growth, supported by the increasing adoption of IL-17 and IL-23 biologics, TYK2 inhibitors, biosimilar launches, and patient-centric treatment models. Expanding healthcare infrastructure in emerging regions further strengthens long-term growth prospects.

Leading Players include: AbbVie, Novartis, Eli Lilly, Johnson & Johnson, Amgen, Pfizer, Bristol Myers Squibb, UCB, and Sun Pharma.

Segmentation Analysis
By Product
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors)
• Small Molecules (JAK inhibitors, TYK2 inhibitors)
• Conventional Systemics (Methotrexate, Cyclosporine, Acitretin)
• Topical Agents (used as adjunctive care)
• Biosimilars
• Supportive Care Medications

By Platform
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By Technology
• Biologic & Biosimilar Development Platforms
• Small Molecule Innovation (JAK/TYK2 inhibitors)
• Digital Dermatology & AI Skin Monitoring Tools
• Biomarker & Precision Medicine Diagnostics

By End Use
• Hospitals & Dermatology Clinics
• Specialty Immunology Centers
• Academic & Research Institutes
• Homecare Settings

By Application
• Plaque Psoriasis
• Psoriatic Arthritis with Skin Involvement
• Other Severe Psoriasis Variants

Summary:
Biologics dominate the landscape, particularly IL-17 and IL-23 inhibitors, while TYK2 inhibitors (e.g., deucravacitinib) are the fastest-growing oral therapy class. Biosimilars are lowering treatment costs and expanding patient access, especially in Europe and Asia.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71343/moderate-to-severe-psoriasis-market

Regional Analysis
North America
• Largest market with high biologic penetration, FDA approvals of TYK2 inhibitors, and robust reimbursement frameworks.
• U.S. leads in adoption of IL-23 biologics and digital dermatology platforms.
Europe
• Strong presence with EMA-approved biologics and biosimilars, government reimbursement systems, and patient registries.
• Germany, France, and the UK drive regional market expansion.
Asia-Pacific
• Fastest-growing region due to increasing prevalence of psoriasis, rising healthcare investments, and biosimilar launches in China, India, and Japan.
Middle East & Africa
• Gradual growth with expanding dermatology centers but limited biologic access due to affordability barriers.
Latin America
• Moderate growth, led by Brazil and Mexico, with improving access to biologics and biosimilars.

Regional Summary:
North America and Europe dominate the global market, while Asia-Pacific is projected to post the fastest CAGR through 2034, supported by rising awareness, growing healthcare access, and biosimilar affordability.

Market Dynamics
Key Growth Drivers
• Rising global prevalence of psoriasis and comorbidities.
• Expanding adoption of biologics, JAK inhibitors, and TYK2 inhibitors.
• Biosimilar launches improving affordability and access.
• Growth of AI-powered dermatology and digital monitoring solutions.

Key Challenges
• High treatment costs of biologics and novel small molecules.
• Variable patient response and adherence challenges.
• Underdiagnosis and limited access in low-resource settings.

Latest Trends
• FDA/EMA approvals of next-generation IL-23 inhibitors and TYK2 inhibitors.
• Rapid expansion of biosimilars in Europe and Asia.
• Adoption of teledermatology and AI-based monitoring apps.
• Combination therapy trials to enhance efficacy and durability.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71343

Competitor Analysis
Major Players in the Market:
• AbbVie - Market leader with Humira (adalimumab) and Skyrizi (IL-23 inhibitor).
• Novartis - Strong with Cosentyx (IL-17 inhibitor).
• Eli Lilly - Leading with Taltz (IL-17 inhibitor).
• Johnson & Johnson - Tremfya (IL-23 inhibitor) and Stelara (IL-12/23 inhibitor).
• Amgen - Expanding in biosimilars and biologics.
• Pfizer - Strong JAK/TYK2 inhibitor pipeline.
• Bristol Myers Squibb - Innovator with deucravacitinib (TYK2 inhibitor).
• UCB - Dermatology-focused biologics pipeline.
• Sun Pharma - Expanding generics and biosimilars in dermatology.

Competitive Dynamics:
The market is innovation-driven, with AbbVie, Novartis, and Eli Lilly dominating biologics, while BMS and Pfizer push innovation in TYK2 and JAK inhibitors. Biosimilars are intensifying competition globally, particularly in Europe and Asia-Pacific.

Conclusion
The moderate to severe psoriasis market is evolving rapidly as biologics, small molecules, and biosimilars reshape dermatology care. Despite affordability and access challenges, the long-term outlook through 2034 is highly positive.

Key Takeaways:
• Market expected to grow at a CAGR of 8% (2025-2034).
• IL-17 and IL-23 inhibitors dominate, while TYK2 inhibitors are the fastest-growing segment.
• North America and Europe lead adoption, while Asia-Pacific posts fastest growth.
• Biosimilars and digital dermatology tools expand access and affordability.
• Competition centers on biologics innovation, biosimilar strategies, and precision dermatology solutions.

Overall, the moderate to severe psoriasis market offers significant opportunities for global pharma leaders, biotech innovators, and digital health providers to advance treatment and improve patient outcomes worldwide.

This report is also available in the following languages : Japanese (中等度から重度の乾癬市場), Korean (중등도에서 중증 건선 시장), Chinese (中度至重度牛皮癣市场), French (Marché du psoriasis modéré à sévère), German (Markt für mittelschwere bis schwere Psoriasis), and Italian (Mercato della psoriasi da moderata a grave), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @https://exactitudeconsultancy.com/reports/71343/moderate-to-severe-psoriasis-market#request-a-sample

Our More Reports:

Cutaneous Squamous cell Carcinoma Market
https://exactitudeconsultancy.com/reports/71380/cutaneous-squamous-cell-carcinoma-market

Dystrophic Epidermolysis Bullosa Market
https://exactitudeconsultancy.com/reports/71382/dystrophic-epidermolysis-bullosa-market

Generalized Pustular Psoriasis Market
https://exactitudeconsultancy.com/reports/71384/generalized-pustular-psoriasis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.